The company's validation studies demonstrate that the assay has a 99 percent negative predictive value, which it believes will persuade physicians of its value.
The assay combines high-throughput drug screening of live, patient-derived tumor cells with DNA sequencing and data analysis to match patients with drug therapies.
Analyzing utilization data, Diaceutics found that issues around 13 genetic tests prevent around 78,000 patients from getting personalized, targeted treatments each year.
Founder Mark Harris and Gillian Hooker, VP of clinical development, explain why a more efficient Genetic Health Information Network is critical to the advancement of precision medicine.
There are signs that doctors may be moving away from experimental precision therapy options in favor of immunotherapy and the chance at longer survival.
The new algorithm, called TOPSPIN, complements the company's MMprofiler test. It is considering making TOPSPIN-generated data available to its MMprofiler patients.
The firm announced a 14 percent drop year-over-year in fourth quarter revenues and plans to reduce personnel and other costs to support development of a precision drug it has licensed.
The system allows oncologists to pick treatment regimens using NantHealth's decision support tool, and order them directly through Allscript's EHR system.
At the Personalized Medicine World Conference, stakeholders and the former FDA commissioner discussed how regulation can advance personalized medicine amid political uncertainty.
Notable is adopting Labcyte's Echo acoustic liquid handling platform to screen cancer patients' tumor cells for response to individual and combination therapies.
